Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

Inclisiran is a double-stranded small interfering RNA that suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) translation in the liver, leading to sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins with twice-yearly dosing. The purpos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology Jg. 77; H. 9; S. 1182
Hauptverfasser:	Wright, R Scott, Ray, Kausik K, Raal, Frederick J, Kallend, David G, Jaros, Mark, Koenig, Wolfgang, Leiter, Lawrence A, Landmesser, Ulf, Schwartz, Gregory G, Friedman, Andrew, Wijngaard, Peter L J, Garcia Conde, Lorena, Kastelein, John J P
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 09.03.2021
Schlagworte:	Aged Atherosclerosis - blood Atherosclerosis - diagnosis Atherosclerosis - drug therapy Cholesterol, LDL - antagonists & inhibitors Cholesterol, LDL - blood Clinical Trials, Phase III as Topic - methods Female Humans Hyperlipoproteinemia Type II - blood Hyperlipoproteinemia Type II - diagnosis Hyperlipoproteinemia Type II - drug therapy Male Middle Aged RNA, Small Interfering - pharmacology RNA, Small Interfering - therapeutic use inclisiran lipid-lowering therapy RNA silencing low-density lipoprotein cholesterol ASVCD
ISSN:	1558-3597, 1558-3597
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!